Key points for investors:
- Regulatory: The FDA accepted Scholar Rock's biologics license application (BLA) for apitegromab for children and adults with SMA and assigned a PDUFA date of September 30, 2026. The resubmitted BLA includes two U.S. fill-finish facilities (Catalent Indiana and a second U.S.-based facility), giving Scholar Rock two independent paths to potential approval. The FDA completed an unannounced reinspection of Catalent Indiana and has up to 90 days to classify the facility. Scholar Rock expects ample commercial drug product from the second fill-finish facility in early Q3, ahead of the PDUFA date.
- Europe: MAA review is progressing well; company expects a CHMP opinion near midyear and plans to begin launches in the second half of the year (starting with Germany). EMA reviewers have been kept informed about the Catalent situation.
- Commercial readiness: U.S. and European commercial teams say they are prepared to launch immediately upon approval. Activities include disease awareness campaigns, payer engagements (national, regional, Medicare/Medicaid), site-of-care planning (home infusion capability), specialty pharmacy network expansion, and patient support program (Scholar Rock Supports).
- Pipeline: Ongoing enrollment in OPAL (infants/toddlers with SMA, includes post-Zolgensma patients); planned randomized Phase II FORGE study in FSHD to start midyear (60 patients); development of subcutaneous apitegromab (encouraging Phase I PK/PD data) and SRK-439 (high-potency anti-myostatin antibody) with Phase I dosing ongoing and topline expected later this year.
- Financials / balance sheet: Q1 operating expenses $102M (including $80M noncash stock-based comp); adjusted operating expenses $84M. Cash, cash equivalents and marketable securities of $480M at quarter end (includes $100M drawdown from existing debt facility in March and $98M net proceeds from ATM). Upon FDA approval, the company has an option to draw an additional $150M from the debt facility and plans to monetize a priority review voucher. Company states a disciplined spend focus on launch readiness, supply chain, and R&D.
- Risks / near-term milestones: FDA classification decision for Catalent Indiana (within up to 90 days following reinspection) and the September 30 PDUFA are the principal near-term regulatory milestones. Execution risk includes final FDA facility classification and successful commercialization planning and reimbursement negotiations.
Overall investor takeaways: Scholar Rock has materially de‑risked the apitegromab regulatory path by including a second fill-finish site and securing a September 30 PDUFA date; the company asserts launch readiness and has a solid cash runway ($480M), with additional financing options available upon approval. Key near-term value drivers are the FDA facility classification, the PDUFA decision, the CHMP opinion in midyear, early-Q3 availability of product from the second fill-finish site, and progress in FSHD and subcutaneous/SRK-439 programs.
Sign In
Buy SRRK
